Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Amgen (NQ: AMGN)
234.04 USD  +0.20 (+0.09%)
Streaming Delayed Price  /  Updated: 3:11 PM EST, Dec 11, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 882,549
Open 234.03
Bid (Size) 233.94 (2)
Ask (Size) 233.99 (1)
Prev. Close 233.84
Today's Range 233.03 - 234.97
52wk Range 166.30 - 235.80
Shares Outstanding 661,706,000
Dividend Yield 2.26%
Performance
YTD
+21.96%
+21.96%
1 Month
+6.04%
+6.04%
3 Month
+18.88%
+18.88%
6 Month
+34.03%
+34.03%
1 Year
+20.58%
+20.58%
Top News
More News
Amgen Data From Phase 3 CANDOR Study Combining KYPROLIS® (carfilzomib) And DARZALEX® (daratumumab) To Be Presented During Late-Breaking Session At American Society Of Hematology Annual Meeting
Treatment With KYPROLIS, Dexamethasone and DARZALEX (KdD) Resulted in a Significant Progression-Free Survival (PFS) Benefit Read More
from PR Newswire
Amgen Selects Location For R&D Facility In The South San Francisco Biotechnology Hub
Amgen Signs Lease With Biomed Realty for New Gateway of Pacific Campus Facility Read More
from PR Newswire
More News
Read More
Beyond Cholesterol: Landmark deCODE Study Elucidates Role of Lipoprotein(a) as Major Risk Factor for Heart Disease
from PR Newswire
FDA Approves Amgen's AVSOLA™ (infliximab-axxq), For The Same Indications As Remicade® (infliximab)
from PR Newswire
TQQQ, AAPL, CMCSA, AMGN: Large Inflows Detected at ETF
category ETFs
from ETF Channel
Is Rigel Pharmaceuticals Stock a Buy?
category NVS , GRFS , AMGN , and 2 more.
from Motley Fool
Drugmakers have spent a record $342 billion on M&A in 2019
category Biotechnology , Company Announcements/Warnings , SNY , and 19 more.
from MarketWatch
9 Most Overbought Stocks In The S&P 500
category INCY , Benzinga , relative strength index , and 13 more.
from Benzinga
Bristol-Myers reports positive data on cancer treatment acquired in Celgene deal
category companyNews
from Reuters: Company News
Better Buy: Biogen vs. Amgen
category RHHBY , BIIB , AMGN , and 2 more.
from Motley Fool
UPDATE 1-FDA approves Amgen's biosimilar to J&J's rheumatoid arthritis drug
category companyNews
from Reuters: Company News
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
X